Patents by Inventor David W. Berberich

David W. Berberich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10604488
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: March 31, 2020
    Assignee: Mallinckrodt LLC
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Patent number: 10363251
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat a variety of disorders.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: July 30, 2019
    Assignee: Mallinckrodt LLC
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Publication number: 20190040242
    Abstract: The present invention relates to novel polymer compositions and their use in polyolefin resins. Films and rigid or semi-ridged articles made from these novel polymer compositions provide improved oxygen and/or carbon dioxide barrier protections.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 7, 2019
    Applicant: INVISTA NORTH AMERICA S.A R.L.
    Inventors: Uwe BAYER, David W. BERBERICH, Robert L. JONES, Jr., Anne NEUBIG, Qun SUN
  • Patent number: 9562014
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: February 7, 2017
    Assignee: Mallinckrodt LLC
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Publication number: 20170029432
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
    Type: Application
    Filed: September 2, 2016
    Publication date: February 2, 2017
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Publication number: 20150335638
    Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat a variety of disorders.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 26, 2015
    Inventors: Bobby N. Trawick, David W. Berberich, Christopher W. Grote
  • Patent number: 8921561
    Abstract: The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 30, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Christopher W. Grote, Frank W. Moser, Peter X. Wang, Gary L. Cantrell, David W. Berberich
  • Publication number: 20140370005
    Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
    Type: Application
    Filed: June 26, 2014
    Publication date: December 18, 2014
    Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
  • Publication number: 20140370006
    Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
    Type: Application
    Filed: June 26, 2014
    Publication date: December 18, 2014
    Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
  • Patent number: 8829020
    Abstract: The invention relates generally to anti-angiogenesis agents and related methods of using to anti-angiogenesis agents for biomedical applications including direct monotherapy and combination therapy for treatment of an angiogenesis related condition. In an embodiment, the invention provides a class of opioid compounds and structurally related opioid derivatives exhibiting anti-VEGF activity for use in therapeutic procedures, including phototherapy. Opioid compounds and structurally related opioid derivatives of the invention may be administered alone or in combination with administration of a phototherapy agent and/or other therapeutic agent.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: September 9, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Gary L. Cantrell, Raghavan Rajagopalan, David W. Berberich, Amolkumar Karwa, Richard B. Dorshow
  • Patent number: 8703949
    Abstract: The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis/alkylation reactions for the synthesis of N-alkyl morphinans.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: April 22, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Subo Liao, Peter X. Wang, David W. Berberich, Douglas C. Miller
  • Patent number: 8624030
    Abstract: The present invention provides processes for the demethylation of an N-methyl morphinan comprising a ketone functional group. In particular, the invention provides methods for the protection of the ketone functional group such that impurities are not generated during the demethylation of the N-methyl morphinan.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: January 7, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Peter X. Wang, Tao Jiang, David W. Berberich, Subo Liao
  • Patent number: 8624031
    Abstract: The invention relates to processes for the production of alkaloids without the isolation of intermediates.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: January 7, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Peter X. Wang, Tao Jiang, David W. Berberich
  • Patent number: 8623888
    Abstract: The present invention provides 3-oxy-hydromorphone derivatives, and in particular, 3-ester, 3-carbonate, and 3-sulfonate derivatives of hydromorphone.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: January 7, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Gary L. Cantrell, Robert E. Halvachs, Frank W. Moser, David W. Berberich, Peter X. Wang
  • Patent number: 8614224
    Abstract: The invention generally provides processes and intermediate compounds useful for the production of sinomenine derivatives. In particular, the process may encompass synthetic routes for the production of (+)-sinomenine derivatives and their intermediates.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: December 24, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Peter X. Wang, Tao Jiang, Gary L. Cantrell, David W. Berberich, Bobby N. Trawick, Subo Liao, John Brandt
  • Patent number: 8563727
    Abstract: The present invention provides (+)-morphinanium N-oxide compounds or pharmaceutically acceptable salts thereof. The invention also provides processes for producing (+)-morphinanium N-oxides or pharmaceutically acceptable salts thereof from the corresponding tertiary N-substituted (+)-morphinan compound or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: October 22, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Gary L. Cantrell, Peter X. Wang, Bobby N. Trawick, Christopher W. Grote, David W. Berberich, Hang Sun, Subo Liao
  • Patent number: 8563724
    Abstract: The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: October 22, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Christopher W. Grote, Gary L. Cantrell, Peter X. Wang, Bobby N. Trawick, David W. Berberich
  • Patent number: 8563725
    Abstract: The present invention provides processes for the preparation of saturated ketone morphinan compounds from a morphinan comprising an allyl alcohol ring moiety, wherein the final product has a low metal content. In particular, the invention provides processes that utilize isomerization reactions catalyzed by transition metal catalysts and the subsequent removal of the transition metal using metal scavengers.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: October 22, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Tao Jiang, Peter X. Wang, David W. Berberich
  • Patent number: 8461337
    Abstract: The invention generally provides processes and intermediate compounds useful for the production of sinomenine derivatives. In particular, the process may encompass synthetic routes for the production of (+)-sinomenine derivatives and their intermediates.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: June 11, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Peter X. Wang, Tao Jiang, Gary L. Cantrell, David W. Berberich, Bobby N. Trawick, Subo Liao, John Brandt
  • Publication number: 20130137874
    Abstract: The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 30, 2013
    Applicant: Mallinckrodt LLC
    Inventors: Christopher W. Grote, Frank W. Moser, Peter X. Wang, Gary L. Cantrell, David W. Berberich